152P Treatment (tx) patterns and clinical outcomes in unresectable stage III epidermal growth factor receptor-mutation positive (EGFRm) non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT): Interim analysis of a global real-world (RW) study

There is an unmet need for patients (pts) with unresectable stage III EGFRm NSCLC who receive CRT. Consolidative immunotherapy has limited efficacy and no EGFR-TKIs are approved in this setting. We report interim data from a global, retrospective RW study of pts with unresectable stage III EGFRm NSCLC who received CRT. Data were extracted from medical records of pts (≥18 years) with unresectable stage III EGFRm NSCLC diagnosed 1 Jan 2016–31 Dec 2019, who received CRT +/- durvalumab (durva) as standard of care (data cutoff: 31 Dec 2022). Study outcomes were: mutation testing and tx patterns, RW progression-free survival (rwPFS), time to next tx or death (rwTTNTD) and overall survival (rwOS). Pts (N=73) from South Korea (68%), US (25%), Japan (5%) and UK (1%) had a median age of 66 years; 56% were female, 91% had ECOG PS 0–1, 41% were current/former smokers, 92% had adenocarcinoma, 64% and 36% had EGFR Ex19del and L858R mutations, respectively. Tumour PD-L1 expression was negative (<1%), low (1–49%), high (≥50%) and unknown in 27%, 18%, 12% and 42% of pts, respectively. Overall, 85% received CRT alone and 15% received CRT + durva; 55% and 41% received concurrent or sequential CRT, respectively (4% unknown CRT sequence). CRT comprised platinum + paclitaxel (78%), platinum + pemetrexed (11%) and platinum/other + chemotherapy (11%). 78% of pts completed first tx, 12% discontinued due to adverse events, 16% discontinued for other reasons (of which 5% progressive disease). Of 60 pts (82%) who received a subsequent tx, 44 (73%) received EGFR-TKIs; 44 pts (60%) received a second subsequent tx (61% EGFR-TKIs). Median rwPFS, rwTTNTD and rwOS from CRT initiation were 9.0 months (95% confidence interval [CI] 6.1, 10.4), 10.7 months (95% CI 9.0, 14.1) and 60.9 months (95% CI 44.4, 66.9), respectively. In this analysis of pts with unresectable stage III EGFRm NSCLC receiving CRT in RW clinical practice, the majority received EGFR-TKIs as subsequent tx following CRT. Despite relatively short rwPFS, rwOS was prolonged, which may be attributed to subsequent EGFR-TKI use.